Claims in Truvada Print Ad Lead to Gilead Warning

The FDA has sent Gilead Sciences an untitled letter about a direct-to-consumer print advertisement for its HIV treatment Truvada, saying the ad overstates the efficacy of the drug, makes unsubstantiated claims and minimizes risks. The ad misleadingly suggests that patients taking Truvada (emtricitabine/tenofovir disoproxil fumarate) as part of an HIV combination therapy will be able to maintain undetectable levels of HIV-1 RNA and increased CD4 cell counts long-term, the Division of Drug Marketing, Advertising and Communications letter says.
Washington Drug Letter